Treatment options in pemphigus

Giornale Italiano di Dermatologia e Venereologia

Volumn 144, Issue 4, 2009, Pages 351-361

  Bystryn, J C ^a   Habib, N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Azathioprine; Cyclophosphamide; Methotrexate; Mycophenolate mofetil; Pemphigus, Ftherapy; Rituximab; Steroids

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; GOLD; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; TETRACYCLINE; TRIAMCINOLONE ACETONIDE;

ACUTE PSYCHOSIS; ANAMNESIS; ARTHRALGIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEPRESSION; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; FLUSHING; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; IMMUNOADSORPTION; LUNG EDEMA; MEMORY DISORDER; MULTIPLE CYCLE TREATMENT; PEMPHIGUS; PHYSICAL EXAMINATION; PLASMAPHERESIS; REVIEW; SEIZURE; SEPSIS; SIDE EFFECT; SKIN ATROPHY; SKIN BIOPSY; TASTE DISORDER;

EID: 72249113833     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Stanley JR. Pemphigus. In: Freedberg IF, Eisen AZ, Wulff K, Austen KF, Goldsmith LA. Fitzpatrick's Dermatology in General Medicine. New York: McGraw Hill; 1999. p. 654.
2. Bystryn JC, Grando SA. A novel explanation for acantholysis in pemphigus vulgaris: the basal cell shrinkage hypothesis. J Am Acad Dermatol 2006;54:513-516
3. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000;42:422-427
4. Bystryn JC. Interpretation of immunofluorescence tests in dermatology. Progr Dermatol 1985;19:1-8.
5. Jablonska S, Churrelski TP, Beutner H. Utilization of immunofluorescence in the diagnosis of bullous diseases, lupus erythematosus and certain other dermatoses. Int J Dermatol 1975;14:83-100.
6. Ruocco E, Aurilia A, Ruocco V. Precautions and suggestions for pemphigus patients. Dermatology 2001;203:201-207 (Pubitemid 33035975)
7. Landau M, Brenner S. Histopathologic findings in drug-induced pemphigus. Am J Dermatopathol 1997;19:411-414 (Pubitemid 27467171)
8. Brenner S, Bialy-Golan A, Anhalt GJ. Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 36:919-923,1997. (Pubitemid 27265902)
9. Bystryn JC. How should pemphigus be treated? J Eur Acad Dermatol Venereol 2002;16:562-563
10. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An Update. Arch Dermatol 1996;132:203-212
11. Czernik A, Bystryn JC. Kinetics of response to conventional treatment in patients with pemphigus vulgaris. Arch Dermatol 2008;144:682-683 (Pubitemid 351724436)
12. Jiao D, Natow S, Bystryn JC. Treatment of pemphigus with IVIg. J Am Acad Dermatol 2002;47:358-363
13. Engineer L, Bohl KC, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 2000;43:1049-1057
14. Rutter A, Luger TA. High-dose intravenous immunoglobulins: An approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 2001;44:1010-1023 (Pubitemid 32493454)
15. Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009;60:595-603.
16. Lolis M, Bystryn JC. Effectiveness of IVIg with or without a cytotoxic drug in the treatment of pemphigus. J Invest Dermatol 2008;128:S10.
17. Auerback R, Bystryn JC. Effect of plasmapheresis and immunosuppressive therapy of intercellular antibodies in pemphigus vulgaris. Arch Dermatol 1979;115:728-730
18. Turner M.S., Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2000;43:1058-1064
19. Bystryn JC. Plasmapheresis therapy of pemphigus. Arch Dermatol 1988;124:1702-1704
20. Tan-Lin R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 1990;22:35.
21. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001;45:679-90.
22. Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticosteroids. Arch Dermatol 1996;132:1435-9.
23. Toth GG, Jonkman MF. Therapy of Pemphigus. Clin Dermatol 2001;19:761-767
24. Sabir S, Werth V. Pulse Glucocorticoids. Dermatol Clin 2000;18:437-46.
25. Yeh SW, Sami N, Ahmed RA. Treatment of Pemphigus Vulgaris. Am J Clin Dermatol 2005;6:327-342
26. Fox LP, Pandya AG. Pulse intravenous cyclophosphamide therapy for dermatologic disorders. Dermatol Clin 2000;18:459-473
27. Pasricha JS, Khaitan BK, Raman RS, Chandra M. Dexamethasone- cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995;34:875-882
28. Mentink L, Mackenzie M, Toth G, Laseur M, Lambert F, Veeger N et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris. Arch Dermatol 2006;142:570-6.
29. Bystryn JC. Adjuvant therapy of pemphigus. Arch Dermatol 1984;120:941.
30. Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000;136:868-872 (Pubitemid 30604285)
31. Dutz JP, Ho VC. Immunosuppressive agents in dermatology. Dermatol Clin 1998;16:235-247
32. Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol 1999;135:1275-1276 (Pubitemid 29493297)
33. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007;57:622-628 (Pubitemid 47384928)
34. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008;6:366-373
35. Basset N, Guillot B, Michel B, Meynadier J, Guilhou JJ. Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol 1987;123:783-785
36. Werth V, Fivenson D, Pandya A, Chen D, Rico MJ, Albrecht J et al. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol 2008;144:25-32.
37. Chrysomallis F, Ioannides D, Teknetzis A, Panagiotidou D, Minas A. Treatment of oral pemphigus vulgaris. Int J Dermatol 1994;33:803-807
38. Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000;136:868-872
39. Lester RS, Knowles SR, Shear NH. The risks of systemic corticosteroid use. Dermatol Clin 1998;16:277-318
40. Nishimura J, Ikuyama S. Glucocorticoid-induced osteoporosis: pathogenesis and management. J Bone Min Metab 2000;18:350-352